Palibon Starterpackung (Paliperidone Palmitate)

Paliperidone palmitate, the active ingredient in Palibon Starterpackung, is an atypical antipsychotic presented as an intramuscular injection for depot administration. It is used in the maintenance treatment of schizophrenia in adults. GNH USA supplies Palibon Starterpackung as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

GNH USA supplies Palibon Starterpackung as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Paliperidone palmitate is an atypical antipsychotic indicated for schizophrenia and related psychotic disorders.

- Schizophrenia: helps maintain symptom control and reduce relapse risk in stabilized adult patients. - Schizoaffective disorder: contributes to long‑term management of psychotic symptoms when combined with standard mood‑stabilising therapy. - Bipolar I disorder (maintenance): used as adjunctive therapy to sustain mood stability and prevent manic or depressive episodes. - Psychotic relapse prevention: provides a once‑monthly or once‑every‑three‑months depot injection to ensure adherence. - Acute agitation (off‑label): may be considered when rapid symptom control is needed, though not a primary indication. - Maintenance therapy after oral stabilization: offers a switch from oral antipsychotics to a long‑acting injectable formulation.

Paliperidone palmitate may cause a range of adverse reactions, some of which are more frequently observed than others.

Common Side Effects: - Injection site pain or erythema: mild discomfort at the injection site. - Weight gain: gradual increase in body weight during treatment. - Somnolence: feeling unusually sleepy or fatigued. - Extrapyramidal symptoms: mild tremor, rigidity or restlessness. - Hyperprolactinemia: elevated prolactin levels, potentially causing menstrual changes. - Constipation: reduced bowel motility leading to hard stools.

Serious or Rare Side Effects: - Neuroleptic malignant syndrome: rare but life‑threatening reaction with fever and muscle rigidity. - Tardive dyskinesia: potentially irreversible involuntary movements. - Severe orthostatic hypotension: marked drop in blood pressure upon standing. - Seizures: increased risk in susceptible individuals. - Cardiac arrhythmias: QT‑interval prolongation that may lead to arrhythmias. - Allergic reactions: anaphylaxis or severe skin rash.

When prescribing Paliperidone palmitate, clinicians should consider several safety aspects.

- Cardiovascular assessment: evaluate for history of arrhythmias or QT prolongation. - Metabolic monitoring: track weight, glucose and lipid levels regularly. - Prolactin monitoring: assess for menstrual disturbances or galactorrhea. - CNS effects: monitor for signs of sedation, dizziness or extrapyramidal symptoms. - Pregnancy and lactation: weigh benefits against potential risks; use only if clearly needed. - Store at 2‑8°C: keep refrigerated, protect from light, do not freeze or shake.

Paliperidone palmitate can interact with other medicines, affecting its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase paliperidone levels and risk of toxicity. - CNS depressants: additive sedation and respiratory depression risk. - QT‑prolonging agents: combined effect may heighten arrhythmia risk.

Moderate Interactions (Monitor Closely): - CYP2D6 substrates (e.g., metoprolol): may experience altered plasma concentrations. - Antihistamines: can enhance anticholinergic side effects. - Anticholinergic drugs: may increase risk of constipation and urinary retention.